KURN — Kuros Biosciences AG Cashflow Statement
0.000.00%
Last trade - 00:00- CH₣1.27bn
- CH₣1.26bn
- $85.81m
Annual cashflow statement for Kuros Biosciences AG, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | fx Final | fx Final | fx Final |
| Net Income/Starting Line | -12.9 | -10.5 | -16.8 | -14.9 | -3.8 |
| Depreciation | |||||
| Non-Cash Items | 1.03 | 1.72 | 7.49 | 6.21 | 9.05 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.831 | -0.385 | -1.4 | -4.26 | -4.67 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -9.84 | -5.97 | -7.7 | -9.85 | 3.57 |
| Capital Expenditures | -0.234 | -0.409 | -0.419 | -0.363 | -1.26 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Cash from Investing Activities | -0.234 | -0.409 | -0.419 | -0.363 | -1.26 |
| Financing Cash Flow Items | -1.46 | 0 | -2.55 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 18.2 | 6.65 | 3.38 | -0.19 | 1.52 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 8.08 | 0.264 | -4.78 | -11 | 4.33 |